Immuneering IMRX
NASDAQ IMRX
$3.87 +0.22 (+6.03%)
As of: Nov 10, 2026 · 3:45 PM EST

Immuneering (IMRX) Total Non-Current Liabilities (2022)

Updated

Immuneering (IMRX) recorded Total Non-Current Liabilities of $8.45 million in Q2 2022, up 0.8% from the prior quarter.

Analysis

Immuneering (IMRX) Total Non-Current Liabilities (2022) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Eli Lilly 1,264.65 Bn 1,238.27 Bn 20.46 Bn 60.81 Bn
2 Johnson & Johnson 677.74 Bn 597.60 Bn 17.30 Bn 102.65 Bn
3 AbbVie 517.10 Bn 485.11 Bn 13.12 Bn 117.60 Bn
4 Merck 362.23 Bn 325.17 Bn 13.19 Bn 79.95 Bn
5 Novartis Ag 315.90 Bn 276.16 Bn 11.24 Bn 48.34 Bn
6 Astrazeneca 289.40 Bn 266.24 Bn 12.86 Bn 33.91 Bn
7 Amgen 249.90 Bn 201.56 Bn 7.58 Bn 76.12 Bn
8 Gilead Sciences 209.15 Bn 184.26 Bn 6.73 Bn 36.05 Bn
9 Pfizer 165.88 Bn 113.23 Bn 12.56 Bn 96.04 Bn
10 Immuneering 246.36 Mn -378.47 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2022 8.45 Mn
Mar 31, 2022 8.38 Mn
API Access

Immuneering Total Non-Current Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=total-non-current-liabilities&ticker=IMRX&period=max&api_key=YOUR_API_KEY